The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Open accessAbstract
Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial. Patients and Methods: Overall, 471 patients in Australia, New Zealand, and the United Kingdom with previously untreated, unresectable mCRC were randomly assigned to the following: capecitabine; capecitabine plus bevacizumab (CB); or capecitabine, bevacizumab, and mitomycin (CBM). We compared CB with capecitabine and CBM with capecitabine for progression-free survival (PFS). Secondary end points included overall survival (OS), toxicity, response rate (RR), and quality of life (QOL). Results: Median PFS was 5.7 months for capecitabine, 8.5 months for CB, and 8.4 months for CBM (capecitabine v CB: hazard ratio [HR], 0.63; 95% CI, 0.50 to 0.79; P < .001; C v CBM: HR, 0.59; 95% CI, 0.47 to 0.75; P < .001). After a median follow-up of 31 months, median OS was 18.9 months for capecitabine and was 16.4 months for CBM; these data were not significantly different. Toxicity rates were acceptable, and all treatment regimens well tolerated. Bevacizumab toxicities were similar to those in previous studies. Measures of overall QOL were similar in all groups. Conclusion: Adding bevacizumab to capecitabine, with or without mitomycin, significantly improves PFS without major additional toxicity or impairment of QOL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, the addition of bevacizumab to standard first‐line chemotherapy regimens significantly improved progression‐free survival.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [273]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Kabbinavar, F. F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Liebérman, G., Griffing, S., & Bergsland, E. K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,711
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,596
Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H. P., Miller, K. D., Kabbinavar, F. F., Bergsland, E. K., Ngai, J., Holmgren, E. B., Wang, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm086 · Cited by 940
Flagged first, then by citations
Research works printed but not linked: 2
- Presta LG, 1997, Cancer Res, 57, 4593
- Wagner AD, 2009, Cochrane Database Syst Rev, 3, CD005392
Cited by
Sorted by citations
Items 101–200 of 413
André, T., Falcone, A., Shparyk, Y. V., Moiseenko, F. V., Polo, E., Csőszi, T., Bragagnoli, A. S. C., Liposits, G. I., Chmielowska, E., Aubel, P., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00334-x · Cited by 45
Self-citationPrinciples of Molecular Utility for CMS Classification in Colorectal Cancer Management
Rejali, L., Asl, R. S., Sanjabi, F., Fatemi, N., Aghdaei, H. A., Niasar, M. S., Moghadam, P. K., Mojarad, E. N., Mini, E., & Nobili, S. (2023) · Cancers · doi:10.3390/cancers15102746 · Cited by 50
Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies
Riechelmann, R. P., & Grothey, A. F. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016676703 · Cited by 43
Current and advancing treatments for metastatic colorectal cancer
Sanz‐García, E., Grasselli, J., Argilés, G., Elez, M. E., & Tabernero, J. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1108405 · Cited by 42
Colorectal Cancer: From Genetic Landscape to Targeted Therapy
Bali, M. E., Bakkach, J., & Mechita, M. B. (2021) · Journal of Oncology · doi:10.1155/2021/9918116 · Cited by 43
Murakami, M., Zhao, S., Zhao, Y., CHOWDHURY, N. F., Yu, W., Nishijima, K., Takiguchi, M., Tamaki, N., & Kuge, Y. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1624 · Cited by 41
Razenberg, L. G. E. M., van Gestel, Y. R. B. M., Lemmens, V. E. P. P., de Hingh, I. H. J. T., & Creemers, G. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.12.006 · Cited by 41
Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer
Schofield, P. E., Stockler, M. R., Zannino, D., Tebbutt, N. C., Price, T. J., Simes, R. J., Wong, N., Pavlakis, N., Ransom, D. T., Moylan, E. J., et al. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2792-8 · Cited by 41
Self-citationRole of Biologics in First-Line Treatment of Colorectal Cancer
Mahipal, A., & Grothey, A. F. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.018382 · Cited by 42
Price, T. J., Bruhn, M. A., Lee, C. K., Hardingham, J. E., Townsend, A. R., Mann, K. P., Simes, J., Weickhardt, A., Wrin, J. W., Wilson, K., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.37 · Cited by 39
Self-citationTsai, H.-T., Marshall, J. L., Weiss, S., Huang, C.-Y., Warren, J. L., Freedman, A. N., Fu, A. Z., Sansbury, L. B., & Potosky, A. L. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt019 · Cited by 39
Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
Ulivi, P., Marisi, G., & Passardi, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8712 · Cited by 40
Gouverneur, A., Salvo, F., Berdaï, D., Moore, N. D., Fourrier‐Réglat, A., & Noïze, P. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.08.001 · Cited by 41
Aparicio, T., Bouché, O., François, É., Rétornaz, F., Barbier, E., Taı̈eb, J., Kirscher, S., Etienne, P.-L., Faroux, R., Akouz, F. K., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.030 · Cited by 39
Xiao, B., Wang, W., & Zhang, D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s166151 · Cited by 40
Dai, F., Shu, L., Bian, Y., Wang, Z., Yang, Z., Chu, W., & Gao, S. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0125-6 · Cited by 38
Nerini, I. F., Cesca, M., Bizzaro, F., & Giavazzi, R. (2016) · 癌症：英文版 · doi:10.1186/s40880-016-0123-1 · Cited by 38
Ilić, I., Јаnkovic, S., & Ilić, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161912 · Cited by 38
Alahmari, A. K., Almalki, Z. S., Alahmari, A. K., & Guo, J. J. (2016) · Europe PMC (PubMed Central) · Cited by 37
Palethorpe, H. M., Tomita, Y., Smith, E., Pei, J. V., Townsend, A. R., Price, T. J., Young, J. P., Yool, A. J., & Hardingham, J. E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030653 · Cited by 36
Self-citationPotential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada
Gotfrit, J., Shin, J., Mallick, R., Stewart, D. J., & Wheatley‐Price, P. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0314 · Cited by 38
Current opinion on optimal treatment for colorectal cancer
Price, T. J., Segelov, E., Burge, M., Haller, D. G., Ackland, S. P., Tebbutt, N. C., Karapetis, C. S., Pavlakis, N., Sobrero, A. F., Cunningham, D., et al. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.37 · Cited by 36
Self-citationPatterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia
Parakh, S., Wong, H., Rai, R., Ali, S. S., Field, K. M., Shapiro, J. D., Wong, R., Nott, L. M., Gibbs, P., & Yip, D. (2015) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2015.06.001 · Cited by 35
Bailey, C. H., Jameson, G., Chao Sima, A., Fleck, S., White, E., Hoff, D. D. V., & Weiss, G. J. (2012) · Journal of Cancer · doi:10.7150/jca.3.7 · Cited by 35
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015
Aranda, E., Aparicio, J., Alonso, V., García‐Albéniz, X., Alfonso, P. G., Salazar, R., Valladares, M., Vera, R., Viéitez, J. M., & García‐Carbonero, R. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1434-4 · Cited by 36
Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives
Marques, I. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i44.7955 · Cited by 34
Feliú, J., Salud, A., Safont, M. J., Girón, C. G., Aparicio, J., Vera, R., Serra, O., Casado, E., Jorge, M., Escudero, P., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.346 · Cited by 34
Gulhati, P., Yin, J., Pederson, L., Schmoll, H., Hoff, P. M., Douillard, J., Hecht, J. R., Tournigand, C., Tebbut, N. C., Chibaudel, B., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa020 · Cited by 34
Hurwitz, H. I., Bekaii‐Saab, T., Bendell, J. C., Cohn, A. L., Kozloff, M. F., Roach, N., Mun, Y., Fish, S. M., Flick, E. D., & Grothey, A. A. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.03.001 · Cited by 35
Petrelli, F., Cabiddu, M., & Barni, S. (2011) · Medical Oncology · doi:10.1007/s12032-011-9958-0 · Cited by 34
An Updated Meta-Analysis of Fatal Adverse Events Caused by Bevacizumab Therapy in Cancer Patients
Huang, H., Zheng, Y., Zhu, J., Zhang, J., Chen, H., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089960 · Cited by 32
Price, T. J., Hardingham, J. E., Lee, C. K., Townsend, A. R., Wrin, J., Wilson, K., Weickhardt, A. J., Simes, R. J., Murone, C., & Tebbutt, N. C. (2013) · Cancer Medicine · doi:10.1002/cam4.75 · Cited by 35
Self-citationClinical trial design in older adults with cancer—The need for new paradigms
Lichtman, S. M. (2012) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2012.03.002 · Cited by 33
Bruhn, M. A., Townsend, A. R., Lee, C. K., Shivasami, A., Price, T. J., Wrin, J., Arentz, G., Tebbutt, N. C., Hocking, C. M., Cunningham, D., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28698 · Cited by 34
Self-citationAdvances and new perspectives in the treatment of metastatic colon cancer
Recondo, G. (2014) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v6.i7.211 · Cited by 31
Sellier, F., Bories, E., Sibertin-Blanc, C., Griffiths, K., Dahan, L., Giovannini, M. F., Gaudart, J., Seitz, J. F., Laugier, R., Caillol, F., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.09.121 · Cited by 31
MicroRNAs and Tumor Vasculature Normalization: Impact on Anti-Tumor Immune Response
Matejuk, A., Collet, G., Nadim, M., Grillon, C., & Kiéda, C. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-013-0231-4 · Cited by 30
Xie, H., Lafky, J. M., Morlan, B. W., Stella, P. J., Dakhil, S. R., Gross, G. G., Loui, W. S., Hubbard, J. M., Alberts, S. R., & Grothey, A. F. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920910913 · Cited by 29
Jang, H. J., Kim, B. J., Kim, J. H., & Kim, H. S. (2017) · Oncotarget · doi:10.18632/oncotarget.20314 · Cited by 30
Qi, W., Fu, S., Zhang, Q., & Guo, X. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.02.007 · Cited by 29
Alfonso, P. G., Grande, E., Polo, E., Afonso, R., Reina, J. J., Jorge, M., Campos, J. M., Martínez, V., Ángeles, C., & Montagut, C. O. (2014) · Angiogenesis · doi:10.1007/s10456-014-9433-6 · Cited by 29
Zhao, M.-J., Yu, Z., Li, Z., Tang, J., Xu, L., & Liu, L. (2016) · Oncology Reports · doi:10.3892/or.2016.5231 · Cited by 31
Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model
Heijmen, L., ter Voert, E. E. G. W., Punt, C. J. A., Heerschap, A., Oyen, W. J. G., Bussink, J., Sweep, F. C. G. J., Laverman, P., Span, P. N., de Geus‐Oei, L., et al. (2014) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1564 · Cited by 28
Bevacizumab in elderly patients with metastatic colorectal cancer
Sclafani, F., & Cunningham, D. (2013) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2013.08.006 · Cited by 28
Self-citationSuccesses and Limitations of Targeted Cancer Therapy in Colon Cancer
Köhne, C. (2014) · Progress in tumor research · doi:10.1159/000356436 · Cited by 27
Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer
Khattak, M. A., Townsend, A. R., Beeke, C., Karapetis, C. S., Luke, C., Padbury, R., Maddern, G. J., Roder, D. M., & Price, T. J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.029 · Cited by 28
Self-citationChan, D. L. H., Pavlakis, N., Shapiro, J. D., Price, T. J., Karapetis, C. S., Tebbutt, N. C., & Segelov, E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135599 · Cited by 26
Self-citationCho, T., Shiozawa, E., Urushibara, F., Arai, N., Funaki, T., Takehara, Y., Tazawa, S., Misawa, M., Homma, M., Norose, T., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.5959 · Cited by 28
Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer
Gill, S., Berry, S. R., Biagi, J., Butts, C., Buyse, M. E., Chen, E., Jonker, D., Marginean, C. E., Samson, B., Stewart, J., et al. (2011) · Current Oncology · doi:10.3747/co.v18is2.941 · Cited by 27
The safety of monoclonal antibodies for treatment of colorectal cancer
Berger, M. D., & Lenz, H. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1167186 · Cited by 26
Oral drugs in the treatment of metastatic colorectal cancer
Kwakman, J. J. M., & Punt, C. J. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1186649 · Cited by 27
Rossi, A., Torri, V., Garassino, M. C., Porcu, L., & Galetta, D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.012 · Cited by 27
Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer
Gill, S., Berry, S. R., Biagi, J. J., Butts, C. A., Buyse, M. E., Chen, E., Jonker, D. J., Maginean, C., Samson, B., Stewart, J., et al. (2011) · Current Oncology · doi:10.3747/co.v18i0.958 · Cited by 25
Pinto, C., Antonuzzo, L., Porcu, L., Aprile, G., Maiello, E., Masi, G., Petrelli, F., Scartozzi, M., Torri, V., & Barni, S. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.08.006 · Cited by 25
Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 25
Quality of life of patients with gastrointestinal cancers undergoing chemotherapy
Tantoy, I. Y., Cooper, B. A., Dhruva, A., Cataldo, J. K., Paul, S. M., Conley, Y. P., Hammer, M. J., Kober, K. M., Levine, J. D., & Miaskowski, C. A. (2018) · Quality of Life Research · doi:10.1007/s11136-018-1860-1 · Cited by 25
Lau, D. K., Fong, C., Arouri, F., Cortez, L., Katifi, H., Gonzalez-Exposito, R., Razzaq, M. B., Su, L., Macklin-Doherty, A., Hernandez, M. A., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10857-8 · Cited by 24
Self-citationWong, N. S., Fernando, N. H., Nixon, A. B., Cushman, S. M., Aklilu, M., Bendell, J. C., Morse, M. A., Blobe, G. C., Ashton, J., Pang, H., et al. (2011) · PubMed · Cited by 25
Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents
Escalante, C. P., Chang, Y.-C., Liao, K.-P. E., Rouleau, T., Halm, J. K., Bossi, P., Bhadriraju, S., Brito-Dellan, N., Sahai, S. K., Yusuf, S. W., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3310-3 · Cited by 24
André, T., Saunders, M. P., Kanehisa, A., Gandossi, E., Fougeray, R., Amellal, N., & Falcone, A. (2020) · Future Oncology · doi:10.2217/fon-2019-0786 · Cited by 23
Self-citationÉvrard, S. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.07.061 · Cited by 23
Cohen, R., Raeisi, M., Chibaudel, B., Shi, Q., Yoshino, T., Zalcberg, J. R., Adams, R., Cremolini, C., Cutsem, E. V., Heinemann, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114160 · Cited by 24
Self-citationYuan, S., Yang, W.-B., Shi, L., Ye, Z., Shi, H., & Zhou, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035629 · Cited by 22
Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab
Zhu, X., Tian, X., Yu, C., Hong, J., Fang, J., & Chen, H. (2016) · Medicine · doi:10.1097/md.0000000000004232 · Cited by 22
Chen, Y.-X., Yang, Q., Kuang, J., Chen, S.-Y., Wei, Y., Jiang, Z.-M., & Xie, D.-R. (2014) · Gastroenterology Research and Practice · doi:10.1155/2014/594930 · Cited by 22
Performance of capecitabine in novel combination therapies in colorectal cancer
Pouya, F. D., Rasmi, Y., Camcı, İ. Y., Tutar, Y., & Nemati, M. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.1920247 · Cited by 21
Chionh, F. J. M., Gebski, V., Al-Obaidi, S. J., Mooi, J. K., Bruhn, M. A., Lee, C. K., Chüeh, A. C., Williams, D. S., Weickhardt, A. J., Wilson, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-03952-y · Cited by 21
Self-citationBevacizumab in colorectal cancer: current and future directions
Yeung, Y. H., & Tebbutt, N. C. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.104 · Cited by 21
Self-citationIntegration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer
Jain, V. K. S., Hawkes, E. A., & Cunningham, D. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.04.001 · Cited by 21
Self-citationJary, M., Vernerey, D., Lecomte, T., Dobi, E., Ghiringhelli, F., Monnien, F., Godet, Y., Kim, S. C. H., Bouché, O., Fratté, S., et al. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-1059 · Cited by 21
Rico, G. T., Price, T. J., Tebbutt, N. C., Hardingham, J. E., Lee, C. K., Buizen, L., Wilson, K., Gebski, V., & Townsend, A. R. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.12.002 · Cited by 21
Self-citationManeikytė, J., Baušys, A., Leber, B., Horvath, A., Feldbacher, N., Höefler, G., Strupas, K., Stiegler, P., & Schemmer, P. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.35513 · Cited by 21
Management of locally advanced and metastatic colon cancer in elderly patients
Kurniali, P. C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i8.1910 · Cited by 20
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD
de With, M., van Doorn, L., Maasland, D. C., Mulder, T. A. M., Hoop, E. O., Mostert, B., Homs, M. Y. V., Bouazzaoui, S. E., Mathijssen, R. H. J., van Schaik, R. H. N., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114232 · Cited by 20
Xu, R., Xu, C., Liu, C., Cui, C., & Zhu, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s171724 · Cited by 20
Zhang, C., Tan, Y., & Xu, H. (2019) · International Journal of Colorectal Disease · doi:10.1007/s00384-019-03362-7 · Cited by 20
Carter, H. E., Zannino, D., Simes, R. J., SCHOFIELD, D. J., Howard, K., Zalcberg, J. R., Price, T. J., & Tebbutt, N. C. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.09.028 · Cited by 19
Self-citationA multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer
Ferrarotto, R., Machado, K. K., Mak, M. P., Shah, N. N., Takahashi, T. K., Costa, F. P., Overman, M. J., Kopetz, S., & Hoff, P. M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.008 · Cited by 19
Gabizón, A., Tahover, E., Golan, T., Geva, R., Perets, R., Amitay, Y., Shmeeda, H., & Ohana, P. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00897-3 · Cited by 19
Clarke, S. J., Burge, M., Cordwell, C., Gibbs, P., Reece, W. H. H., & Tebbutt, N. C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-120 · Cited by 18
Self-citationTranquart, F., Dujardin, P., Bouché, O., Marcus, C. D., Borg, C., Manzoni, P., Douillard, J., Labbé-Devilliers, C., Terrebonne, E., Smith, D. M., et al. (2017) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/s-0043-122497 · Cited by 18
The “angiogenetic ladder”, step-wise angiogenesis inhibition in metastatic colorectal cancer
Giampieri, R., Scartozzi, M., Prete, M. D., Fulli, A., Faloppi, L., Bianconi, M., Maccaroni, E., & Cascinu, S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.004 · Cited by 17
Lv, C., Wu, S., Zheng, D., Wu, Y., Yao, D., & Yu, X. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1458 · Cited by 17
González-Vacarezza, N., Alonso, I., Arroyo, G., Martínez, J., de Andrés, F., LLerena, A., & Estévez‐Carrizo, F. E. (2016) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2015-0027 · Cited by 17
Zhang, G., Zhou, X., & Lin, C. (2015) · Europe PMC (PubMed Central) · Cited by 17
Clarke, S. J., Burge, M., Feeney, K., Gibbs, P., Jones, K. L., Marx, G. M., Molloy, M. P., Price, T. J., Reece, W. H. H., Segelov, E., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229900 · Cited by 19
Self-citationInfluence of vascular normalization on interstitial flow and delivery of liposomes in tumors
Ozturk, D., Yonucu, S., Yιlmaz, D., & Ünlü, M. B. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/4/1477 · Cited by 17
Yoshida, M., Goto, M., Kii, T., Nishitani, H., Kawabe, S., Kuwakado, S., Asaishi, K., Miyamoto, T., & Higuchi, K. (2013) · Digestion · doi:10.1159/000343943 · Cited by 16
Chitkara, A., Kaur, N., Desai, A., Mehta, D., Anamika, F., Sarkar, S., Gowda, N., Sethi, P. S., Thawani, R., & Chen, E. Y.-S. (2023) · Cancer Medicine · doi:10.1002/cam4.6662 · Cited by 15
The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer
Fakih, M. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.20 · Cited by 17
Modulation of Tumor Vasculature Network: Key Strategies
Taleb, M., Mohammadkhani, N., Bahreini, F., Ovais, M., & Nie, G. (2022) · Small Structures · doi:10.1002/sstr.202100164 · Cited by 16
Shu, C., Sun, P., Xie, H., Huang, W., Qi, J., & Ma, Y. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s237182 · Cited by 15
Hurwitz, H. I., & Lyman, G. H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7031 · Cited by 16
Strategies of Sequential Therapies in Unresectable Metastatic Colorectal Cancer: A Meta-Analysis
Asmis, T. R., Berry, S. R., Cosby, R., Chan, K., Coburn, N. G., & Rother, M. (2014) · Current Oncology · doi:10.3747/co.21.2146 · Cited by 15
Cao, C., Wang, J., Bunjhoo, H., Xu, Y., & Fang, H. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.631579 · Cited by 15
Stein, A., Petersen, V., Schulze, M., Seraphin, J., Hoeffkes, H., Valdix, A., Schroeder, J., Herrenberger, J., Boxberger, F., Leutgeb, B., et al. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.961649 · Cited by 15
Betge, J., Barat, A., Murphy, V., Hielscher, T., van Grieken, N. C. T., Belle, S., Zhan, T., Härtel, N., Kripp, M., Bacon, O., et al. (2016) · Digestion · doi:10.1159/000449412 · Cited by 15
Bai, L., Wang, F., Li, Z.-Z., Ren, C., Zhang, D., Zhao, Q., Lu, Y., Wang, D., Ju, H., Qiu, M., et al. (2016) · Medicine · doi:10.1097/md.0000000000004531 · Cited by 15
Kwakman, J. J. M., Baars, A., Boot, H., Pruijt, H., Winther, S. B., Pfeiffer, P., & Punt, C. J. A. (2017) · Acta Oncologica · doi:10.1080/0284186x.2016.1278459 · Cited by 15
Burzykowski, T., Coart, E., Saad, E. D., Shi, Q., Sommeijer, D. W., Bokemeyer, C., Díaz‐Rubio, E., Douillard, J., Falcone, A., Fuchs, C. S., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11750 · Cited by 15
Self-citation
Metadata
- Authors
- Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., Broad, A., Ganju, V., Ackland, S. P., Forgeson, G., Cunningham, D., Saunders, M. P., Stockler, M. R., Chua, Y., Zalcberg, J. R., Simes, R. J., & Price, T. J.
- Affiliations
- The University of Sydney (AU)
- From Austin Health; Peter MacCallum Cancer Centre; Frankston Hospital, Melbourne; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney; Sir Charles Gairdner Hospital, Perth; Geelong Hospital, Geelong; Canberra Hospital, Canberra; Queen Elizabeth Hospital, Adelaide; Calvary Mater Newcastle Hospital, Newcastle, Australia; Royal Marsden Hospital, London; Christie Hospital, Manchester, United Kingdom; Christchurch Hospital, Christchurch; and Palmerston North...
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2010-07-01
- Volume
- 28
- Issue
- 19
- Pages
- 3191-3198
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2122152991
- Cited by
- 413
- References
- 20
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 18 · 2023: 19 · 2022: 15 · 2021: 19 · 2020: 25 · 2019: 23 · 2018: 23 · 2017: 29 · 2016: 45 · 2015: 39 · 2014: 39 · 2013: 47 · 2012: 28
- FWCI
- 16.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0507-10154)
- Cancer Australia
- Cancer Institute NSW
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, capecitabine, bevacizumab, mitomycin C, first-line chemotherapy, progression-free survival, overall survival, quality of life, treatment toxicity, anti-VEGF therapy
- MeSH terms
- Bevacizumab, Capecitabine, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Diarrhea, Female, Fluorouracil, Humans, Hypotension, Male, Middle Aged, Neoplasm Metastasis, Quality of Life, Thrombocytopenia, Colorectal Neoplasms, Mitomycin, Treatment Outcome, Australasia, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
